Pharmaceuticals

Rise In Gene Therapy Driving The Growth Of The Market Due To Advancements In Genetic Engineering Is Supporting Development Across The Familial Mediterranean Fever Pharmaceuticals Market

May 19, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Will Be The Estimated Market Size Of The Familial Mediterranean Fever Pharmaceuticals Market By 2030?

The familial mediterranean fever pharmaceuticals market has shown significant expansion over recent years. Its valuation is predicted to increase from $1.72 billion in 2025 to $1.81 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.1%. This past growth can be attributed to the proven effectiveness of colchicine, the genetic prevalence observed in Mediterranean populations, the scarcity of alternative therapeutic options, a rise in disease awareness, and more refined diagnostic criteria.

The familial mediterranean fever pharmaceuticals market is projected to experience robust expansion over the forthcoming years. It will grow to $2.21 billion in 2030 at a compound annual growth rate (CAGR) of 5.1%. This anticipated growth during the forecast period is propelled by factors such as higher diagnosis rates beyond endemic regions, the increasing embrace of biologics, the widening scope of orphan drug programs, enhanced genetic screening, and a heightened emphasis on preventing long-term complications. Key trends for the upcoming period encompass the sustained dependence on colchicine therapy, the rising application of interleukin-1 inhibitors, an increase in biologic treatments for resistant FMF cases, a greater emphasis on averting amyloidosis, and advancements in genetic diagnosis facilitating earlier treatment.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23397&type=smp

Which Major Factors Are Contributing To The Development Of The Familial Mediterranean Fever Pharmaceuticals Market?

The expanding application of gene therapy is anticipated to propel the familial Mediterranean fever (FMF) pharmaceuticals market forward. Gene therapy functions as a medical strategy, altering or substituting defective genes to address or avert illnesses at their genetic source. This surge in gene therapy stems from progress in genetic engineering, facilitating accurate identification and rectification of genetic conditions, thereby presenting possible remedies for ailments previously considered incurable. For familial Mediterranean fever (FMF) pharmaceuticals, gene therapy offers a beneficial approach by targeting the fundamental mutations within the MEFV (Mediterranean fever) gene, potentially leading to a lasting or permanent solution instead of mere symptom control. As an illustration, in July 2024, the American Society of Gene & Cell Therapy (ASGCT), a US-based non-profit organization, reported the initiation of 76 gene therapy trials during the second quarter of 2024, marking a 25% increase from the prior quarter. Consequently, the advancement of gene therapy is fostering growth in the familial Mediterranean fever (FMF) pharmaceuticals market.

Which Segment Groups Define The Familial Mediterranean Fever Pharmaceuticals Market Landscape?

The familial mediterranean fever pharmaceuticals market covered in this report is segmented –

1) By Drug Type: Colchicine, Interleukin-1 Inhibitors, Anti-IL-6 Drugs

2) By Route Of Administration: Oral, Injectable

3) By End Users: Hospitals, Clinical Diagnostic Laboratories, Other End Users

Subsegments:

1) By Colchicine: Oral Colchicine, Intravenous Colchicine

2) By Interleukin-1 Inhibitors: Anakinra, Canakinumab, Rilonacept

3) By Anti-IL-6 Drugs: Tocilizumab, Off-Label IL-6 Receptor Antagonists, Refractory FMF Supportive IL-6 Modulation

What Trends Are Driving Changes In The Familial Mediterranean Fever Pharmaceuticals Market?

Leading companies within the familial mediterranean fever pharmaceuticals market are concentrating on precise biologic treatments, including dual interleukin-1 (IL-1a and IL-1ß) blockade mechanisms and orphan drug designation pathways, with the goal of achieving long-term disease remission and broadening therapeutic choices for individuals with autoinflammatory conditions. These dual interleukin-1 blockade approaches utilize heterodimeric hybrid proteins that attach with strong affinity to both IL-1a and IL-1ß cytokines concurrently, thereby neutralizing the inflammatory process that contributes to the development of familial Mediterranean fever and associated disorders. As an illustration, in November 2024, R-Pharm Group, a pharmaceutical firm based in Russia, was granted U.S. Food and Drug Administration (FDA) Orphan Drug Designation for Goflikicept, a new heterodimeric hybrid protein designed to target both IL-1a and IL-1ß, intended for treating familial Mediterranean fever (FMF) and idiopathic recurrent pericarditis (IRP). The company has finished Phase 2/3 clinical trials for IRP and secured marketing approval in Russia, while concurrently progressing with a Phase 2 study for FMF across Turkey, Russia, and Armenia, which solidifies IL-1 blockade as a prominent strategy for achieving enduring remission in autoinflammatory diseases.

Who Are The Major Companies Operating In The Familial Mediterranean Fever Pharmaceuticals Market?

Major companies operating in the familial mediterranean fever pharmaceuticals market are Novartis International AG, Swedish Orphan Biovitrum AB, Granules Pharmaceuticals Inc., Hikma Pharmaceuticals plc, Camber Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Amgen Inc., Indena S.p.A., Harman Finochem, Alchem International, Honour Lab Ltd., Maithri Drugs Pvt. Ltd., Vital Laboratories Pvt. Ltd., Enomark Biotech Pvt. Ltd., Gonane Pharma, Ennature Biopharma, R-Pharm Group, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited

Access The Complete Familial Mediterranean Fever Pharmaceuticals Market Report:

https://www.thebusinessresearchcompany.com/report/familial-mediterranean-fever-pharmaceuticals-global-market-report

Which Region Is The Primary Market For The Familial Mediterranean Fever Pharmaceuticals Market?

Middle East was the largest region in the familial mediterranean fever pharmaceuticals market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the familial mediterranean fever pharmaceuticals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Familial Mediterranean Fever Pharmaceuticals Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=23397&type=smp

Browse Through More Reports Similar to the Global Familial Mediterranean Fever Pharmaceuticals Market 2026, By The Business Research Company

Anti Infective Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-global-market-report

Pharmaceuticals Market 2026

https://www.thebusinessresearchcompany.com/report/pharmaceuticals-market

Anticoccidial Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anticoccidial-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795